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 The control group consisted of 170 patients with AODM, se-
lected by year of birth, who were followed up by the endocrinology 
outpatient clinic between 2012 and 2014. The patients’ files were 
reviewed concerning treatment for diabetes, specifically the use of 
DPP4i. Both groups were compared for gender, treatment with 
DPP4i, age, and calendar year of consultation with a 2-sample  t 
test. The χ 2 test and the Wilcoxon rank-sum test were used for cat-
egorical and continuous variables, respectively. We compared ex-
posure to DPP4i in both groups with adjustment for confounders 
such as age, gender, and calendar year of visit with multiple logis-
tic regression models. Effect of exposure was expressed in terms of 
odds ratios (OR) along with their 95% confidence intervals (CI). 
Analyses were carried out with Stata software (version 13.1, 2014; 
StataCorp, College Station, TX, USA). All tests were considered 
statistically significant at  p < 0.05. 
 Between January 2007 and July 2013, we identified 93 BP pa-
tients. Among these, 23 (24.7%; 12 women/11 men) were diabetic, 
9 of whom were treated with DPP4i. The mean age at inclusion in 
the case series was 77.6 years (68–93 years). The average follow-up 
was 55.3 months (32–73 months) ( Table  1 ). Patients developed 
BP between 5 months and over 4 years after the introduction of 
DPP4i. Of the 9 patients, 5 were on vildagliptin ± metformin, 3 
were on sitagliptin ± metformin, and 1 was on vildagliptin/metfor-
min (later replaced by sitagliptin/metformin) combination. In 7 
cases, the association between drug intake and BP onset was clas-
sified as “possible,” which represents a probability of less than 50% 
for DPP4i to have caused the disease. Two cases (patients 3 and 7) 
developed BP more than 48 months after the first use of DPP4i and 
were classified as unlikely.
 A total of 170 nondermatological control patients (57 wom-
en/113 men) were selected, with a mean age of 76.5 years. Use of 
DPP4i was found in 9 out of 23 (39.1%) BP patients with AODM 
and in 57 out of 170 (33.5%) diabetic control patients. The crude 
OR for DPP4i use in diabetic BP patients was 1.27 (95% CI, 0.52–
3.12,  p = 0.596). When the effect of gender, age, and calendar year 
was accounted for, the adjusted OR increased to 2.48 (95% CI, 
0.75–8.3,  p = 0.137).
 An increasing number of patients who developed BP during 
treatment with DPP4i has been reported, raising the question 
about a causal relationship  [3–10] . In France, there has been an 
average of 10 cases of possible DPP4i-induced BP cases per year 
from 2008 to 2012  [12, 13] .
 We observed a prevalence of 39% of DPP4i in cases and 33% in 
controls. When the effect of gender, age, and year was accounted 
for, there was a nonsignificant trend towards more use of DPP4i 
in BP patients. Most diabetic patients with BP had a history of 
vildagliptin use, a molecule already incriminated in a previous 
study  [1] .
 A total of 24.7% of the BP patients were diabetic, with a similar 
proportion of women and men (25 and 24.4% respectively), where-
as in the general Swiss population aged 75 years or older, the prev-
 An increasing number of reports suggest that inhibitors of the 
dipeptidyl-peptidase IV (DPP4i) are implicated in the develop-
ment of bullous pemphigoid (BP)  [1–8] . We investigated BP pa-
tients diagnosed in our center (Department of Dermatology and 
Venereology, Lausanne University Hospital Centre) between Jan-
uary 2007, the year in which the first DPP4i was introduced in 
Switzerland, and July 2013 to assess whether the use of DPP4i in 
diabetic patients is potentially related to the development of BP. 
We searched the database of the laboratory of dermatopathology 
with the keyword “bullous pemphigoid” between January 2007 
and July 2013. We next identified patients with a definite diagnosis 
of BP with or without adult onset diabetes mellitus (AODM). The 
diagnosis of BP was based on typical or consistent clinical features, 
typical or compatible histological findings, and positive immuno-
pathological studies, including direct and indirect immunofluo-
rescence microscopy, and enzyme-linked immunosorbent assays 
(ELISA) for BP180 and BP230  [9] . If serum was not available for 
testing, diagnosis was based on the presence of 3 of 4 well-estab-
lished clinical criteria for BP in patients having linear deposits of 
C3 and/or IgG along the epidermal basement membrane as de-
tected by direct immunofluorescence microscopy: age >70 years 
and absence of atrophic scarring, mucosal involvement, and pre-
dominant bullous lesions on the neck and head  [10] .
 The files of diabetic patients with BP were systematically ana-
lyzed with regard to (1) antidiabetic treatment(s); (2) comor-
bidities; (3) history of skin diseases; and (4) chronology between 
BP diagnosis, treatment, and onset and duration of the DPP4i 
treatment(s). The association between BP development and the 
intake of DPP4i for each patient was assessed according to the 
World Health Organization and Uppsala Monitoring Centre 
(WHO-UMC) scale, a standardized causality assessment scale of 
adverse drug reactions  [11] , to allow direct comparison with the 
aforementioned study  [1] .
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alence of AODM is approximately 15% in men and 11% in women 
 [14] . Our findings support previous reports suggesting an associa-
tion between AODM and BP  [15, 16] .
 This is the first study to investigate the potential role of DPP4i 
in triggering BP in the Swiss population. Based on the available 
data, an association between the onset of BP and the use of DPP4i 
cannot be shown. Further prospective studies are needed to vali-
date our findings.
 Key Message 
 Our retrospective case-control study raises the awareness that 
BP might be a potential side effect of DPP4i.
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 Table 1.  Demographics and characteristics of the BP cases with type-2 diabetes treated with DPP-4 inhibitors
Patient/
gender/
age, years
Gliptin type Gliptin 
at onset 
(yes/no)
Gliptin 
intake prior 
to BP onset, 
months
BP outcome Gliptin 
at last 
follow-up 
(yes/no)
Comor bidi-
ties/other 
therapies 
[9 – 11]
Causality 
drug 
induction 
[8]
1/M/70 Vildagliptina
Saxagliptin/metforminb
Vildagliptinc
Sitagliptin/metformin
Yes 12 Relapse at 39 months after the initial 
episode, currently on MTX 15 mg/week 
45 months of follow-up
Yes – Possible
2/F/84 Sitagliptin/metformin Yes 36 Remission after doxycycline 
and nicotinamide
Occasional itch
48 months of follow-up
No – Possible
3/M/73 Vildagliptin Yes >48 Remission after topical corticosteroids
52 months of follow-up
No – Unlikely
4/F/70 Vildagliptin/metformin Yes 5 Last relapse at 78 months after the initial 
episode, 3 relapses in total treated with 
topical corticosteroid courses
45 months of follow-up
Yes – Possible
5/M/68 Vildagliptind 
Sitagliptin/metformin
Yes 30 Remission on MTX 10 mg/week and 
dermocorticoids
32 months of follow-up
No Dementia Possible
6/M/80 Sitagliptin No, stopped 
24 months 
before
48 Remission after topical corticosteroids
Occasional itch
63 months of follow-up
No – Possible
7/M/85 Vildagliptin/metformin Yes >48 Remission after topical corticosteroids 
68 months of follow-up
Yes Spirono-
lactone intake
Unlikely
8/M/93 Vildagliptin Yes 21 Remission after topical corticosteroids 
72 months of follow-up
Yes – Possible
9/M/76 Sitagliptin Yes 10 – 11 Remission after topical corticosteroid 
courses with relapse
73 months of follow-up
Yes Dementia Possible
 BP, bullous pemphigoid; F, female; M, male; MTX, methotrexate. a Switched to saxagliptin/metformin after 36 months. b Switched to vildagliptin 
again after 24 months. c Switched to sitagliptin/metformin after 14 months. d Switched to sitagliptin/metformin after 31 months.
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